

Edgar Filing: Axovant Sciences Ltd. - Form 8-K

Axovant Sciences Ltd.  
Form 8-K  
August 15, 2016

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 15, 2016

Axovant Sciences Ltd.  
(Exact name of registrant as specified in its charter)

Bermuda                                      001-37418                                      Not Applicable  
(State or other jurisdiction of      (Commission File No.)      (I.R.S. Employer Identification No.)  
incorporation)

Clarendon House - 2 Church Street  
Hamilton HM 11                                      Not Applicable  
Bermuda  
(Address of principal executive office)      (Zip Code)

Registrant's telephone number, including area code: +1 (441) 824-8100

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02 Results of Operations and Financial Condition.

On August 15, 2016, Axovant Sciences Ltd. (the "Registrant") issued a press release announcing its financial results for the three months ended June 30, 2016. A copy of this press release is furnished herewith as Exhibit 99.1 to this

Edgar Filing: Axovant Sciences Ltd. - Form 8-K

Current Report and is incorporated herein by reference.

In accordance with General Instruction B.2. of Form 8-K, the information in this Item 2.02, and Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Registrant’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.

---

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Description

99.1 Press Release of Axovant Sciences Ltd., dated August 15, 2016, "Axovant Sciences Announces Expansion of Dementia Pipeline and Reports Financial Results for the First Fiscal Quarter Ended June 30, 2016"

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Axovant Sciences Ltd.

Date: August 15, 2016 By: /s/ Gregory Weinhoff  
Name: Gregory Weinhoff  
Title: Principal Financial Officer

EXHIBIT INDEX

Exhibit  
Number Description

99.1 Press Release of Axovant Sciences Ltd., dated August 15, 2016, "Axovant Sciences Announces Expansion of Dementia Pipeline and Reports Financial Results for the First Fiscal Quarter Ended June 30, 2016"